Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 4/20 | 0.35 |
| ▸ | S100A4 | P26447 | 3/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694568 | 0.79 | GAA (0.38) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL5093999 | 0.79 | TDP2 (0.38) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL2822167 | 0.75 | PDCD1 (0.40) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL18485263 | 0.75 | TDP2 (0.35) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL6667756 | 0.72 | ALDH1A1 (0.46) | CCNA2CDK2TDP2CES1MEN1 | |
| SCHEMBL2363208 | 0.71 | CHEK1 (0.36) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL18471620 | 0.71 | TDP2 (0.33) | CCNA2CDK2TDP2NSD2PAX8 | |
| SCHEMBL331804 | 0.69 | TDP2 (0.43) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL7913644 | 0.69 | TDP1 (0.39) | TDP1CDC25BS100A4 | |
| SCHEMBL9963984 | 0.68 | PTPRC (0.46) | TDP2NSD2PAX8ABL1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531500-B1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| US-8912216-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8614226-B2 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2531500-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038960-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 183/4885CDK2 668/4885TDP2 2939/4885 |
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | CCNA2 183/4885CDK2 668/4885TDP2 2939/4885 |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | CCNA2 206/4885CDK2 254/4885TDP2 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.